RNA interference inhibition of matrix metal loprotei nase-1 prevents melanoma metastasis by reducing tumor collagenase activity and angiogenesis

被引:74
作者
Blackburn, Jessica S.
Rhodes, C. Harker
Coon, Charles I.
Brinckerhoff, Constance E.
机构
[1] Dartmouth Hitchcock Med Ctr, Dept Biochem, Lebanon, NH 03766 USA
[2] Dartmouth Hitchcock Med Ctr, Norris Cotton Canc Ctr, Dept Med, Lebanon, NH 03766 USA
[3] Dartmouth Hitchcock Med Ctr, Dept Pathol, Lebanon, NH 03766 USA
关键词
D O I
10.1158/0008-5472.CAN-07-1791
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Melanoma incidence is increasing worldwide, and metastatic melanoma is almost completely resistant to every known therapy. New approaches to treating melanoma are urgently needed, and a greater understanding of the biology of melanoma invasion and metastasis will aid in their creation. A high proportion of invasive melanomas have a constitutively active Raf/mitogen-activated protein kinase/extracellular signal- regulated kinase (MEK/ERK) signaling cascade; however, the downstream effectors of ERK signaling that contribute to melanoma invasion and metastasis are unknown. ERK signaling drives the production of the interstitial collagenase matrix metalloproteinase-1(MMP-1), which is expressed specifically by invasive melanomas. Using short hairpin RNAs (shRNA) to knock down MMP-1 expression in a human melanoma cell line, we investigated the role of MMF-1 in melanoma metastasis in a xenograft model. Knockdown of MMP-1 had no effect on primary tumor growth, but reduction of MMF-1 expression significantly decreased the ability of the melanoma to metastasize from the orthotopic site in the dermis to the lung. Mechanistically, tumor cells expressing MMP-1 shRNAs had diminished collagenase activity, which is required for tumor cell invasion. Additionally, attenuation of MMP-1 expression reduced angiogenesis. These results show, for the first time, that targeted inhibition of MMP-1, a single effector of the Raf/MEK/ERK signaling cascade, prevents the progression of melanoma from a primary to metastatic tumor and, as such, may represent a useful therapeutic tool in controlling this disease.
引用
收藏
页码:10849 / 10858
页数:10
相关论文
共 38 条
[11]   Extracellular matrix-driven matrix metalloproteinase production in endothelial cells: Implications for angiogenesis [J].
Haas, TL ;
Madri, JA .
TRENDS IN CARDIOVASCULAR MEDICINE, 1999, 9 (3-4) :70-77
[12]   Metalloproteinases and their inhibitors in tumor angiogenesis [J].
Handsley, MM ;
Edwards, DR .
INTERNATIONAL JOURNAL OF CANCER, 2005, 115 (06) :849-860
[13]   Matrix metalloproteinases in human melanoma [J].
Hofmann, UB ;
Westphal, JR ;
van Muijen, GNP ;
Ruiter, DJ .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2000, 115 (03) :337-344
[14]   Matrix metalloproteinases in human melanoma cell lines and xenografts: increased expression of activated matrix metalloproteinase-2 (MMP-2) correlates with melanoma progression [J].
Hofmann, UB ;
Westphal, JR ;
Waas, ET ;
Zendman, AJW ;
Cornelissen, IMHA ;
Ruiter, DJ ;
van Muijen, GNP .
BRITISH JOURNAL OF CANCER, 1999, 81 (05) :774-782
[15]   Overexpression of collagenase 1 (MMP-1) is mediated by the ERK pathway in invasive melanoma cells -: Role of BRAF mutation and fibroblast growth factor signaling [J].
Huntington, JT ;
Shields, JM ;
Der, CJ ;
Wyatt, CA ;
Benbow, U ;
Slingluff, CL ;
Brinckerhoff, CE .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (32) :33168-33176
[16]   Expression of collagenase-1 (MMP-1) promotes melanoma growth through the generation of active transforming growth factor-β [J].
Iida, Joji ;
McCarthy, James B. .
MELANOMA RESEARCH, 2007, 17 (04) :205-213
[17]  
Jorgensen K, 2003, CLIN CANCER RES, V9, P5325
[18]  
KOLCH W, 2002, EXPERT REV MOL MED, V25, P1
[19]   Identification of activated matrix metalloproteinase-2 (MMP-2) as the main gelatinolytic enzyme in malignant melanoma by in situ zymography [J].
Kurschat, P ;
Wickenhauser, C ;
Groth, W ;
Krieg, T ;
Mauch, C .
JOURNAL OF PATHOLOGY, 2002, 197 (02) :179-187
[20]   The natural course of cutaneous melanoma [J].
Leiter, U ;
Meier, F ;
Schittek, B ;
Garbe, C .
JOURNAL OF SURGICAL ONCOLOGY, 2004, 86 (04) :172-178